Endocrinol Metab > Volume 37(3); 2022 > Article |
|
AUTHOR CONTRIBUTIONS
Conception or design: S.W.C., Y.J.P. Acquisition, analysis, or interpretation of data: M.J.K., S.W.C., Y.A.K., H.S.C., Y.J.P., D.J.P., B.Y.C. Drafting the work or revising: M.J.K., S.W.C., Y.J.P. Final approval of the manuscript: M.J.K., S.W.C., Y.A.K., H.S.C., Y.J.P., D.J.P., B.Y.C.
Variable |
Univariable |
Multivariablea |
||
---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Age at RAI therapy, yr | ||||
20-39 | 1.36 (0.81-2.29) | 0.245 | ||
40-59 | 1 (reference) | |||
≥60 | 1.00 (0.60-1.78) | 0.988 | ||
Sex | ||||
Male | 1 (reference) | 1 (reference) | ||
Female | 1.35 (1.01-1.81) | 0.043 | 1.09 (0.73-1.64) | 0.680 |
Time from diagnosis to 1st RAI therapy, yr | ||||
≤1 | 1.09 (0.77-1.55) | 0.621 | 2.08 (1.25-3.47) | 0.005 |
2-4 | 1.40 (1.01-1.95) | 0.044 | 1.68 (1.06-2.66) | 0.028 |
≥5 | 1 (reference) | |||
Goiter size, ga | ||||
<60 | 8.06 (4.70-13.83) | <0.001 | 9.07 (4.74-17.39) | <0.001 |
60-90 | 3.36 (1.90-5.93) | <0.001 | 3.77 (1.99-7.16) | <0.001 |
≥90 | 1 (reference) | 1 (reference) | ||
Mean dosage of ATD, mga | ||||
≤10 | 1.92 (1.34-2.76) | <0.001 | 0.81 (0.47-1.40) | 0.442 |
10-20 | 1.65 (1.19-2.28) | 0.003 | 1.03 (0.66-1.60) | 0.889 |
>20 | 1 (reference) | 1 (reference) | ||
Pre-RAI TSH, μIU/mLa | ||||
<0.1 | 1 (reference) | |||
≥0.1 | 1.51 (1.13-2.03) | 0.006 | 0.89 (0.56-1.40) | 0.607 |
Pre-RAI free T4, ng/dLa | 1 (reference) | |||
≤1.8 | 1.18 (0.89-1.57) | 0.239 | ||
>1.8 | 1 (reference) | |||
Pre-RAI TSHR antibody, %a | ||||
≤30 | 2.58 (1.71-3.89) | <0.001 | 1.68 (1.00-2.82) | 0.050 |
30-60 | 1.73 (1.19-2.49) | 0.004 | 1.24 (0.80-1.91) | 0.335 |
>60 | 1 (reference) | 1 (reference) | ||
48-hr RAIU, % | ||||
≤50 | 0.925 (0.627-1.367) | 0.925 | ||
51-75 | 0.785 (0.574-1.076) | 0.785 | ||
≥75 | 1 (reference) |
Variable |
Univariable |
Multivariablea |
||
---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Age at 2nd RAI therapy, yr | ||||
20-39 | 0.79 (0.44-1.42) | 0.435 | 1.38 (0.64-2.96) | 0.410 |
40-59 | 1 (reference) | 1 (reference) | ||
≥60 | 0.34 (0.13-0.90) | 0.030 | 0.13 (0.03-0.56) | 0.006 |
Sex | ||||
Male | 1 (reference) | |||
Female | 1.12 (0.65-1.94) | 0.688 | ||
Time interval between 1st and 2nd RAI therapies, mo | ||||
<6 | 1 (reference) | 1 (reference) | ||
6-11 | 1.79 (0.97-3.30) | 0.062 | 1.98 (0.94-4.19) | 0.074 |
≥12 | 3.17 (1.39-7.26) | 0.006 | 3.82 (1.15-12.69) | 0.029 |
Goiter size, ga | ||||
<60 | 2.21 (1.08-4.53) | 0.030 | 2.52 (1.09-5.84) | 0.031 |
60-90 | 3.91 (1.81-8.43) | 0.001 | 3.30 (1.38-7.86) | 0.007 |
≥90 | 1 (reference) | 1 (reference) | ||
ATD discontinuation, mob | ||||
<2 | 1 (reference) | 1 (reference) | ||
≥2 | 2.14 (1.12-4.06) | 0.021 | 2.86 (1.08-7.55) | 0.034 |
Mean dosage of ATD, mgb | ||||
≤10 | 2.59 (1.11-6.08) | 0.028 | 1.15 (0.33-3.95) | 0.829 |
10-20 | 1.16 (0.52-2.57) | 0.719 | 0.72 (0.26-1.96) | 0.515 |
>20 | 1 (reference) | 1 (reference) | ||
Pre-RAI TSH, μIU/mLa | ||||
<0.1 | 1 (reference) | 1 (reference) | ||
≥0.1 | 2.30 (1.07-4.92) | 0.033 | 2.48 (0.84-7.33) | 0.099 |
Pre-RAI free T4, ng/dLa | ||||
≤1.8 | 1.27 (0.71-2.27) | 0.417 | ||
>1.8 | 1 (reference) | |||
Pre-RAI TSHR antibody, %a | ||||
≤30 | 1.49 (0.53-4.17) | 0.446 | ||
30-60 | 1.72 (0.76-3.88) | 0.190 | ||
>60 | 1 (reference) | |||
48-hr RAIU, % | ||||
≤50 | 1.08 (0.42-2.78) | 0.869 | ||
51-75 | 0.78 (0.31-1.96) | 0.593 | ||
≥75 | 1 (reference) |
Min Joo Kim
https://orcid.org/0000-0002-9765-9340
Sun Wook Cho
https://orcid.org/0000-0002-7394-3830
Therapeutic Response to Radioactive Iodine Treatment in Graves' Disease.1999 December;14(4)